Brown, S L, Langone, J J, Brinton, L A · Journal of the American Medical Women's Association (1972) · 1998
In 1992, the FDA paused approval of silicone breast implants due to safety concerns, particularly worries about autoimmune diseases like scleroderma. This editorial reviews studies conducted since then and finds that while large increases in connective tissue disease overall were ruled out, studies were too small to detect rare diseases. The authors note that new methodologies for studying conditions like fibromyalgia and chronic fatigue syndrome might help answer whether implants cause a specific syndrome.
This editorial is relevant to ME/CFS research because it discusses methodological challenges in identifying novel disease syndromes and their environmental triggers—issues directly applicable to understanding post-viral and environmentally-associated fatigue conditions. The authors' observation that traditional epidemiologic approaches may miss atypical syndromes highlights the need for improved case definitions and study designs when investigating rare or newly-recognized illnesses.
This editorial does not establish whether silicone implants actually cause autoimmune disease or ME/CFS-like syndromes; it reviews prior studies and identifies their limitations rather than presenting new data. The analysis cannot determine causation or prove that a silicone-related syndrome exists, only that existing evidence is insufficient to rule it out. This is an editorial opinion, not primary research data.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →